Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBFB | Q13951 | 1/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 3/20 | 0.43 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | PDE1A | P54750 | 1/20 | 0.35 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.35 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13594653 | 0.84 | ADRB2 (0.52) | ADRB2PARP1HTTSMN1; SMN2ADORA3 | |
| SCHEMBL10584662 | 0.83 | CBFB (0.40) | CBFBADRB2PARP1ADAMTS5EGLN1 | |
| SCHEMBL13408208 | 0.79 | HTT (0.52) | CBFBADRB2PARP1HTTRPS6KA3 | |
| SCHEMBL21608573 | 0.79 | LMNA (0.48) | CBFBADRB2PARP1HTTNPC1 | |
| SCHEMBL5989876 | 0.79 | ADRB2 (0.42) | CBFBADRB2PARP1HTTADORA3 | |
| SCHEMBL15500371 | 0.79 | ADRB2 (0.42) | CBFBADRB2PARP1HTTSMN1; SMN2 | |
| SCHEMBL8265272 | 0.79 | HRH4 (0.48) | ADRB2PARP1EGLN1HTTRPS6KA3 | |
| SCHEMBL21615514 | 0.79 | ADRB2 (0.42) | CBFBADRB2PARP1HTTSMN1; SMN2 | |
| SCHEMBL6509697 | 0.79 | ADRB2 (0.58) | CBFBADRB2PARP1HTTRPS6KA3 | |
| SCHEMBL3265280 | 0.79 | HTT (0.47) | CBFBADRB2PARP1HTTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200054664-A1 | METABOLIC SUPPLEMENT FORMULATION AND METHODS OF USE FOR TREATING DEPRESSION AND ANXIETY | HAWKINS GERMAINE BERNARD (US) | 2020-02-20 | — | — | US | claimed |
| EP-2445518-A1 | COBALAMIN TAXANE BIOCONJUGATES FOR TREATING EYE DISEASE | Osiris Therapeutics, Inc. (US) | 2012-05-02 | — | — | EP | claimed |
| US-20110166097-A1 | TAXANE COMPOUNDS FOR TREATING EYE DISEASE | OSIRIS THERAPEUTICS, INC. (US) | 2011-07-07 | — | — | US | claimed |
| EP-2320728-A1 | TAXANE COMPOUNDS FOR TREATING EYE DISEASE | Osiris Therapeutics, Inc. (US) | 2011-05-18 | — | — | EP | claimed |
| WO-2010088287-A1 | COBALAMIN TAXANE BIOCONJUGATES FOR TREATING EYE DISEASE | GEBHARD JOHN R (US) | 2010-08-05 | — | — | WO | claimed |
| JP-2010509488-A | — | — | 2010-03-25 | — | — | JP | claimed |
| WO-2010011662-A1 | TAXANE COMPOUNDS FOR TREATING EYE DISEASE | INFLABLOC PHARMACEUTICALS, INC. (US) | 2010-01-28 | — | — | WO | claimed |
| US-20100016256-A1 | Taxane Compounds for Treating Eye Disease | OSIRIS THERAPEUTICS, INC | 2010-01-21 | — | — | US | claimed |
| EP-2139469-A2 | COBALAMIN TAXANE BIOCONJUGATES | Inflabloc Pharmaceuticals, Inc. (US) | 2010-01-06 | — | — | EP | claimed |
| EP-1978997-A1 | TRANSDERMAL DELIVERY OF PHARMACEUTICAL AGENTS | Apollo Life Sciences Limited (AU) | 2008-10-15 | — | — | EP | claimed |
| CN-1126441-A | Amplification of vitamin B12 absorption System Using polymers | BIOTECH AUSTRALIA PTY LTD (AU) | 1996-07-10 | — | — | CN | claimed |
| CN-1126436-A | Vitamin B12 mediated oral delivery systems for GCSF and EPO | BIOTECH AUSTRALIA PTY LTD (AU) | 1996-07-10 | — | — | CN | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| EP-0701448-A1 | AMPLIFICATION OF THE VITAMIN B 12? UPTAKE SYSTEM USING POLYMERS | BIOTECH AUSTRALIA PTY. LIMITED (AU) | 1996-03-20 | — | — | EP | claimed |
| EP-0700295-A1 | VITAMIN B 12? MEDIATED ORAL DELIVERY SYSTEMS FOR GCSF AND EPO | BIOTECH AUSTRALIA PTY. LIMITED (AU) | 1996-03-13 | — | — | EP | claimed |
| EP-0673783-A2 | Recording sheets containing purine, pyrimidine, benzimidazole, imidazolidine, urazole, pyrazole, triazole, benzotriazole, tetrazole, and pyrazine compounds | XEROX CORPORATION (US) | 1995-09-27 | — | — | EP | claimed |
| US-5449720-A | Amplification of the VB12 uptake system using polymers | BIOTECH AUSTRALIA PTY LIMITED (AU) | 1995-09-12 | — | — | US | claimed |
| WO-1994027613-A1 | VITAMIN B12 MEDIATED ORAL DELIVERY SYSTEMS FOR GCSF AND EPO | BIOTECH AUSTRALIA PTY. LIMITED (AU) | 1994-12-08 | — | — | WO | claimed |
| WO-1994027641-A1 | AMPLIFICATION OF THE VITAMIN B12 UPTAKE SYSTEM USING POLYMERS | BIOTECH AUSTRALIA PTY. LIMITED (AU) | 1994-12-08 | — | — | WO | claimed |
| EP-0428260-A2 | Metal surface treatment agents | SANWA LABORATORY LTD. (JP) | 1991-05-22 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016256-A1 | Taxane Compounds for Treating Eye Disease | TTR, BTD, MTHFD1 | CBFB 4111/4885ADRB2 3704/4885PARP1 438/4885 |
| US-20110166097-A1 | TAXANE COMPOUNDS FOR TREATING EYE DISEASE | TTR, BTD, MTHFD1 | CBFB 4111/4885ADRB2 3704/4885PARP1 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.